Rozpoznawanie i leczenie chorych na chłoniaka rozlanego z duzych komórek B

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma that affects patients at all ages and is characterized by an aggressive clinical course. Besides lymph node involvement,DLBCL may affect various organs presenting with differentiated clinical manifestations, therefore constituting an important entity in differential diagnostic of numerous diseases. Approximately 60% of patients may be cured with rituximab and cytotoxic drug based immunochemotherapy, however the prognosis of relapsed and refractory cases is poor. Recent progress in molecular biology enabled better definition of this heterogeneous lymphoma group what might result in treatment individualization and improvement of prognosis. In this publication we discuss the recommendations concerning the diagnosis, treatment and monitoring of patients with DLBCL.